ASCO 2018 | Optimizing treatment for renal cell carcinoma with sequential therapies
In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Robert Figlin, MD, of Cedars-Sinai Medical Center, Los Angeles, CA, discusses the importance of sequential therapies in kidney cancer treatment. Immunotherapies and targeted agents are both mentioned, along with advice for practitioners who do not specialize in kidney cancer.
Transcript (edited for clarity)
So the most important thing in renal cell carcinoma is really the integration of either sequential targeted agents such as pazopanib, sunitinib or cabozantinib, or the integration of immuno-oncology drugs like ipilimumab and nivolumab. I think that as we evolve we’re continuing to treat and accomplish more beneficial results for patients but we’re not clear yet on how to choose the right treatment for the right patient at the right time...
So the most important thing in renal cell carcinoma is really the integration of either sequential targeted agents such as pazopanib, sunitinib or cabozantinib, or the integration of immuno-oncology drugs like ipilimumab and nivolumab. I think that as we evolve we’re continuing to treat and accomplish more beneficial results for patients but we’re not clear yet on how to choose the right treatment for the right patient at the right time. I think it’s hard for a practicing oncologist that sees kidney cancer infrequently. The data sets are growing larger every day. It’s important that they continue to learn about the appropriate use of targeted agents, they learn about the literature and when to use immuno-oncology drugs, they familiarize themselves with the adverse events to manage their patients appropriately, and recognize that likely in kidney cancer it’s the sequential treatment of patients rather than just a single treatment that the patient should receive.
Read more...
